News | January 31, 2022
Pharma industry seeks fiscal support to drive innovation
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Subscribe To Our Newsletter & Stay Updated
